Unsafe
Not Aligned
Patient Risk:
High
Summary
The extracted claims largely discuss generic substitution/market availability, which is not addressed in the provided FDA label sections. Several safety/efficacy-related assertions (e.g., resistance-driven worsening, antimicrobial overuse and resistance) are also not supported by the supplied label text. Only a small subset of safety and use-related content is partially supported (e.g., 2% strength for Centany; local adverse reactions including pruritus/rash; and reassessment if no response in 3–5 days).
Category Scores
Accurate Statements
Clinical effectiveness of mupirocin depends on whether the infection is one the product is labeled to treat.
INDICATIONS AND USAGE: Centany (mupirocin ointment), 2% indicated for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes.
Mupirocin can cause allergic skin reactions such as itching and rash.
ADVERSE REACTIONS: application site reactions and pruritus (1%); contact dermatitis and furunculosis; exfoliative dermatitis and rash (0.3%).
Clinical effectiveness of mupirocin depends on correct frequency and duration of use.
DOSAGE AND ADMINISTRATION: apply three times daily; patients not showing a clinical response within 3 to 5 days should be re-evaluated.
Unsupported Statements
Generic mupirocin cream is available in many markets.
Not addressed in the provided FDA label sections.
Generic mupirocin cream typically replaces the brand-name prescription version of mupirocin topical antibacterial products.
Generic substitution/market replacement not described in the provided label sections.
Generic versions of mupirocin cream use the same active ingredient (mupirocin).
No labeling provided supporting generic formulation equivalence concepts.
Generic mupirocin cream is intended to deliver similar clinical effect when used as directed.
The provided label sections do not discuss generic-vs-brand intent for clinical effect.
Mupirocin products are commonly marketed in strengths like 2% for topical use.
Label shows Centany is 2%, but does not support that products are 'commonly marketed' in many markets/manufacturers.
Exact available strengths of mupirocin products can vary by country and manufacturer.
Not addressed in the provided label sections.
Mupirocin products may be packaged as cream or as ointments even though the active ingredient is the same.
Not addressed in the provided label sections.
Once a product’s exclusivity and patent protections end, multiple manufacturers can market generic mupirocin.
Exclusivity/patent and manufacturer timeline not addressed in the provided label sections.
If a brand never had strong protections covering that specific formulation, multiple manufacturers may market generic mupirocin.
Not addressed in the provided label sections.
Different companies may vary the vehicle (cream base vs ointment base) for mupirocin generics.
Not addressed in the provided label sections.
Different companies may vary the packaging size for mupirocin generics.
Not addressed in the provided label sections.
Different companies may vary the price and pharmacy availability of mupirocin generics.
Not addressed in the provided label sections.
A prescription written for 'mupirocin' or for the generic ingredient with the correct strength usually allows substitution.
Substitution rules are not provided in the supplied label sections.
If a prescription is written as 'brand medically necessary,' the pharmacy may need the prescriber’s permission for substitution of generic mupirocin.
Pharmacy operational/legal substitution guidance is not provided in the supplied label sections.
Generic mupirocin has the same core safety profile as the brand because the active ingredient is the same.
Generic-vs-brand safety equivalence is not discussed in the provided label sections.
Mupirocin can cause local irritation (burning, stinging, redness) at the application site.
Label supports local adverse reactions and pruritus, but does not specify burning/stinging/redness in the provided sections.
Mupirocin may rarely lead to worsening infection if used incorrectly or if the bacteria are resistant.
No such risk/resistance statement appears in the provided label sections.
Overuse or unnecessary use of topical antibiotics like mupirocin can increase the risk of resistance.
Resistance/antibiotic stewardship statements are not included in the provided label sections.
Effectiveness of mupirocin depends on proper use and the specific infection rather than whether it is brand or generic.
Brand vs generic comparison is not addressed in the provided label sections.
Clinical effectiveness of mupirocin depends on proper cleaning before application.
No pre-cleaning instruction is included in the provided label sections.
Clinical effectiveness of mupirocin depends on whether the causative bacteria are susceptible.
Susceptibility/resistance guidance is not explicitly stated in the provided label sections; the indication organisms are provided, but not susceptibility wording.
If symptoms do not improve as expected after using mupirocin, clinicians often reassess diagnosis, resistance, and whether a different treatment is needed.
Label supports re-evaluation if no clinical response within 3 to 5 days, but does not mention 'often reassess' framing, nor 'resistance', nor a 'different treatment needed' rationale.
Contradictions
Important Omissions
The provided claims do not mention the contraindication: history of sensitivity reactions to any components.
Importance:
Moderate
The provided claims omit explicit labeling of the indicated condition and specific causative organisms as the basis for use (impetigo due to Staphylococcus aureus and Streptococcus pyogenes), except partially through an effectiveness-to-labeled-infection general statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many claims extend beyond the provided label (generic substitution/market/legal aspects and resistance/worsening infection/stewardship concepts) and are unsupported by the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the claims are not supported by the provided FDA label sections, particularly generic availability/substitution and resistance-related assertions.
Suggested Improvement
Restrict statements to what the provided label text supports (impetigo indication with listed organisms, dosing frequency of three times daily, re-evaluate if no response within 3–5 days, and adverse reaction types including pruritus and rash). Remove or rephrase generic substitution/market and resistance/overuse claims that are not present in the supplied labeling.